Published finding — does the expert body still believe it?
Intraarterial treatment for acute ischemic stroke does not significantly increase mortality or symptomatic intracerebral hemorrhage rates compared to usual care alone.
TL;DR · AI-generated
In patients with acute ischemic stroke caused by a proximal intracranial occlusion of the anterior circulation, intraarterial treatment administered within 6 hours after stroke onset was effective and safe.
Author-implied confidence
85%
Status
DRAFT
Your position — does this noeme still stand given current evidence?
0% (impossible)
50%
100% (certain)
Proper-scoring-rule preview
Your position is kept on this device until you sign in.
Evidence stream
1 event · 1 snapshot
posterior drift
93% → 93% (0pp · 1 point)
Peer-reviewed paper
Apr 18, 2026
Expert reactions · 0
Sign in to post a take, cite a related claim, or flag a methodological concern.
No reactions yet. Be the first expert to post a take, cite a related claim, or flag a methodological concern.
Source publication
A randomized trial of intraarterial treatment for acute ischemic stroke.
· openalex W2139621750 · s2 93d703fd
Semantically related
Nearest claims in the expert-corpus vector space. Ordered by cosine distance — lower is closer.
0.1187
Intraarterial treatment plus usual care improved 90-day modified Rankin Scale scores compared to usual care alone in patients with acute ischemic stroke from proximal anterior circulation occlusion, with an adjusted common odds ratio of 1.67 (95% CI, 1.21–2.30).
0.1208
Symptomatic intracranial hemorrhage rates do not differ significantly between thrombectomy and standard care groups (6% vs 3%) in patients treated 6-24 hours after stroke onset with clinical-infarct mismatch.
0.1370
Intraarterial treatment within 6 hours of stroke onset increased the rate of functional independence (mRS 0–2) at 90 days by an absolute 13.5 percentage points (32.6% vs. 19.1%) compared to usual care alone.
0.1490
Endovascular thrombectomy in the 6-16 hour window is associated with a numerically lower 90-day mortality rate (14%) compared with medical therapy alone (26%, P=0.05) without a significant increase in symptomatic intracranial hemorrhage (7% vs. 4%, P=0.75).
0.1517
The SWIFT PRIME trial's stated primary conclusion — Stent-retriever thrombectomy plus tPA is superior to tPA alone for proximal anterior-circulation stroke. — replicates in independent cohorts.
0.1535
Ninety-day mortality does not differ significantly between thrombectomy and standard care groups (19% vs 18%) in patients with acute stroke treated 6-24 hours after last known well with clinical-infarct mismatch.